Loading
A phase 3 trial in lung cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC is a phase 3, randomised interventional study registered as NCT06457906 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 340 participants, started 2023-09-01 and due to reach its primary completion in 2027-08-30. Interventions recorded: Experimental group (SRS/SRT/Hypo-RT); Controled group (HA-WBRT). Conditions listed: Small-cell Lung Cancer; Brain Metastases; SRS; Stereotactic Radiotherapy; Whole Brain Radiotherpay; Hippocampal-avoidance. Primary outcome: Cognitive function scores; Meadian OS time. Lung eligibility wording from the registry: "Pathologically (histologically or cytologically) proven diagnosis of small cell lung cancer within 5 years of registration". Sites: China. No results are recorded here; the registry entry is the source.
Shares SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.